{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:48:50Z","timestamp":1790912930975,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"23-24","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s10354-010-0864-4","type":"journal-article","created":{"date-parts":[[2011,1,7]],"date-time":"2011-01-07T07:47:42Z","timestamp":1294386462000},"page":"594-599","source":"Crossref","is-referenced-by-count":18,"title":["The pathophysiology of GD \u2013 current understanding and rationale for existing and emerging therapeutic approaches","Pathophysiologie von Morbus Gaucher \u2013 aktueller Wissensstand und Rationale f\u00fcr vorhandene und zuk\u00fcnftige Therapieans\u00e4tze"],"prefix":"10.1007","volume":"160","author":[{"given":"Derralynn A.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Pastores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"864_CR1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2141.2004.05351.x","volume":"129","author":"M Jmoudiak","year":"2005","unstructured":"Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol, 129: 178\u2013188, 2005","journal-title":"Br J Haematol"},{"key":"864_CR2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bcmd.2006.09.004","volume":"37","author":"R Rozenberg","year":"2006","unstructured":"Rozenberg R, Fox DC, Sobreira E, et al. Detection of 12 new mutations in Gaucher disease Brazilian patients. Blood Cells Mol Dis, 37: 204\u2013209, 2006","journal-title":"Blood Cells Mol Dis"},{"key":"864_CR3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10038-007-0135-4","volume":"52","author":"P Alfonso","year":"2007","unstructured":"Alfonso P, Aznarez S, Giralt M, et al. Mutation analysis and genotype\/phenotype relationships of Gaucher disease patients in Spain. J Hum Genet, 52: 391\u2013396, 2007","journal-title":"J Hum Genet"},{"key":"864_CR4","first-page":"792","volume":"85","author":"P Giraldo","year":"2000","unstructured":"Giraldo P, Pocovi M, Perez-Calvo J, et al. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics. Haematologica, 85: 792\u2013799, 2000","journal-title":"Haematologica"},{"key":"864_CR5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1432-1033.1990.tb19173.x","volume":"191","author":"S Van Weely","year":"1990","unstructured":"Van Weely S, Aerts JM, Van Leeuwen MB. Function of oligosaccharide modification in glucocerebrosidase, a membrane-associated lysosomal hydrolase. Eur J Biochem, 191: 669\u2013677, 1990","journal-title":"Eur J Biochem"},{"key":"864_CR6","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/sj.embor.embor873","volume":"4","author":"H Dvir","year":"2003","unstructured":"Dvir H, Harel M, McCarthy AA, et al. X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep, 4: 704\u2013709, 2003","journal-title":"EMBO Rep"},{"key":"864_CR7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1051\/jbio\/2002196020151","volume":"196","author":"S Fabrega","year":"2002","unstructured":"Fabrega S, Durand P, Mornon JP, et al. The active site of human glucocerebrosidase: structural predictions and experimental validations. J Soc Biol, 196: 151\u2013160, 2002","journal-title":"J Soc Biol"},{"key":"864_CR8","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","volume":"66","author":"V Koprivica","year":"2000","unstructured":"Koprivica V, Stone DL, Park JK, et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet, 66: 1777\u20131786, 2000","journal-title":"Am J Hum Genet"},{"key":"864_CR9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.21362","volume":"84","author":"TH Taddei","year":"2009","unstructured":"Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol, 84: 208\u2013214, 2009","journal-title":"Am J Hematol"},{"key":"864_CR10","first-page":"986","volume":"4","author":"E Beutler","year":"2002","unstructured":"Beutler E, West C. Polymorphisms in glucosylceramide (glucocerebroside) synthase and the Gaucher disease phenotype. Isr Med Assoc J, 4: 986\u2013988, 2002","journal-title":"Isr Med Assoc J"},{"key":"864_CR11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jgm.901","volume":"8","author":"KA McEachern","year":"2006","unstructured":"McEachern KA, Nietupski JB, Chuang WL, et al. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease. J Gene Med, 8: 719\u2013729, 2006","journal-title":"J Gene Med"},{"key":"864_CR12","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1634\/stemcells.2008-0844","volume":"27","author":"IB Enquist","year":"2009","unstructured":"Enquist IB, Nilsson E, Mansson JE, et al. Successful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher disease. Stem Cells, 27: 744\u2013752, 2009","journal-title":"Stem Cells"},{"key":"864_CR13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10409239009090616","volume":"25","author":"GA Grabowski","year":"1990","unstructured":"Grabowski GA, Gatt S, Horowitz M. Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease. Crit Rev Biochem Mol Biol, 25: 385\u2013414, 1990","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"864_CR14","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1194\/jlr.M500547-JLR200","volume":"47","author":"F Ciaffoni","year":"2006","unstructured":"Ciaffoni F, Tatti M, Boe A, et al. Saposin B binds and transfers phospholipids. J Lipid Res, 47: 1045\u20131053, 2006","journal-title":"J Lipid Res"},{"key":"864_CR15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s004010050960","volume":"97","author":"T Pampols","year":"1999","unstructured":"Pampols T, Pineda M, Giros ML, et al. Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant. Acta Neuropathol (Berl), 97: 91\u201397, 1999","journal-title":"Acta Neuropathol (Berl)"},{"key":"864_CR16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1399-0004.1982.tb01445.x","volume":"22","author":"O Nilsson","year":"1982","unstructured":"Nilsson O, Hakansson G, Dreborg S, et al. Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III. Clin Genet, 22: 274\u2013279, 1982","journal-title":"Clin Genet"},{"key":"864_CR17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0009-8981(97)00241-6","volume":"271","author":"R Gornati","year":"1998","unstructured":"Gornati R, Bembi B, Tong X, et al. Total glycolipid and glucosylceramide content in serum and urine of patients with Gaucher's disease type 3 before and after enzyme replacement therapy. Clin Chim Acta, 271: 151\u2013161, 1998","journal-title":"Clin Chim Acta"},{"key":"864_CR18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0005-2760(82)90272-7","volume":"712","author":"O Nilsson","year":"1982","unstructured":"Nilsson O, Mansson JE, Hakansson G, et al. The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher's disease. Biochim Biophys Acta, 712: 453\u2013463, 1982","journal-title":"Biochim Biophys Acta"},{"key":"864_CR19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1015137917508","volume":"25","author":"R Gornati","year":"2002","unstructured":"Gornati R, Berra B, Montorfano G, et al. Glycolipid analysis of different tissues and cerebrospinal fluid in type II Gaucher disease. J Inherit Metab Dis, 25: 47\u201355, 2002","journal-title":"J Inherit Metab Dis"},{"key":"864_CR20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/qjmed\/94.8.399","volume":"94","author":"TM Cox","year":"2001","unstructured":"Cox TM. Gaucher's disease \u2013 an exemplary monogenic disorder. QJM, 94: 399\u2013402, 2001","journal-title":"QJM"},{"key":"864_CR21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","volume":"122","author":"LA Boven","year":"2004","unstructured":"Boven LA, van Meurs M, Boot RG, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol, 122: 359\u2013369, 2004","journal-title":"Am J Clin Pathol"},{"key":"864_CR22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V34.3.331.331","volume":"34","author":"N Pennelli","year":"1969","unstructured":"Pennelli N, Scaravilli F, Zacchello F. The morphogenesis of Gaucher cells investigated by electron microscopy. Blood, 34: 331\u2013347, 1969","journal-title":"Blood"},{"key":"864_CR23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0950-3536(97)80037-6","volume":"10","author":"GM Pastores","year":"1997","unstructured":"Pastores GM. Gaucher's disease. Pathological features. Baillieres Clin Haematol, 10: 739\u2013749, 1997","journal-title":"Baillieres Clin Haematol"},{"key":"864_CR24","first-page":"205","volume":"10","author":"V Barak","year":"1999","unstructured":"Barak V, Acker M, Nisman B, et al. Cytokines in Gaucher's disease. Eur Cytokine Netw, 10: 205\u2013210, 1999","journal-title":"Eur Cytokine Netw"},{"key":"864_CR25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/bcmd.1997.0137","volume":"23","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Evers L, Aerts JM, et al. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis, 23: 201\u2013212, 1997","journal-title":"Blood Cells Mol Dis"},{"key":"864_CR26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bcmd.2003.10.007","volume":"32","author":"A Brautbar","year":"2004","unstructured":"Brautbar A, Elstein D, Pines G, et al. Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells Mol Dis, 32: 214\u2013217, 2004","journal-title":"Blood Cells Mol Dis"},{"key":"864_CR27","first-page":"472","volume":"11","author":"GM Pastores","year":"2010","unstructured":"Pastores GM. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease. Curr Opin Investig Drugs, 11: 472\u2013478, 2010","journal-title":"Curr Opin Investig Drugs"},{"key":"864_CR28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/11318540-000000000-00000","volume":"24","author":"GM Pastores","year":"2010","unstructured":"Pastores GM. Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease. BioDrugs, 24: 41\u201347, 2010","journal-title":"BioDrugs"},{"key":"864_CR29","doi-asserted-by":"crossref","unstructured":"Bracoud L, Ahmad H, Brill-Almon E, et al. Improving the accuracy of MRI spleen and liver volume measurements: a phase III Gaucher disease clinical trial setting as a model. Blood Cells Mol Dis, in press, 2010","DOI":"10.1016\/j.bcmd.2010.10.009"},{"key":"864_CR30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","volume":"122","author":"GA Grabowski","year":"1995","unstructured":"Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med, 122: 33\u201339, 1995","journal-title":"Ann Intern Med"},{"key":"864_CR31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","volume":"64","author":"R Schiffmann","year":"2008","unstructured":"Schiffmann R, Fitzgibbon EJ, Harris C, et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann Neurol, 64: 514\u2013522, 2008","journal-title":"Ann Neurol"},{"key":"864_CR32","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood, 116: 4095\u20134098, 2010","journal-title":"Blood"},{"key":"864_CR33","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","volume":"14","author":"I Ron","year":"2005","unstructured":"Ron I, Horowitz M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet, 14: 2387\u20132398, 2005","journal-title":"Hum Mol Genet"},{"key":"864_CR34","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s11910-010-0102-x","volume":"10","author":"A Velayati","year":"2010","unstructured":"Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep, 10: 190\u2013198, 2010","journal-title":"Curr Neurol Neurosci Rep"},{"key":"864_CR35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcp.21023","volume":"212","author":"M Deganuto","year":"2007","unstructured":"Deganuto M, Pittis MG, Pines A, et al. Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress. J Cell Physiol, 212: 223\u2013235, 2007","journal-title":"J Cell Physiol"},{"key":"864_CR36","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood-2009-02-205708","volume":"114","author":"PM Campeau","year":"2009","unstructured":"Campeau PM, Rafei M, Boivin MN, et al. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood, 114: 3181\u20133190, 2009","journal-title":"Blood"},{"key":"864_CR37","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/hmg\/ddp061","volume":"18","author":"T Farfel-Becker","year":"2009","unstructured":"Farfel-Becker T, Vitner E, Dekel H, et al. No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum Mol Genet, 18: 1482\u20131488, 2009","journal-title":"Hum Mol Genet"},{"key":"864_CR38","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.bcp.2006.12.015","volume":"73","author":"R Steet","year":"2007","unstructured":"Steet R, Chung S, Lee WS, et al. Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase. Biochem Pharmacol, 73: 1376\u20131383, 2007","journal-title":"Biochem Pharmacol"},{"key":"864_CR39","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1021\/jm100198t","volume":"53","author":"L Diaz","year":"2010","unstructured":"Diaz L, Bujons J, Casas J, et al. Click chemistry approach to new N-substituted aminocyclitols as potential pharmacological chaperones for Gaucher disease. J Med Chem, 53: 5248\u20135255, 2010","journal-title":"J Med Chem"},{"key":"864_CR40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.nbd.2004.09.004","volume":"18","author":"D Pelled","year":"2005","unstructured":"Pelled D, Trajkovic-Bodennec S, Lloyd-Evans E, et al. Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol Dis, 18: 83\u201388, 2005","journal-title":"Neurobiol Dis"},{"key":"864_CR41","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nchembio.368","volume":"6","author":"DS Ong","year":"2010","unstructured":"Ong DS, Mu TW, Palmer AE, et al. Endoplasmic reticulum Ca2+ increases enhance mutant glucocerebrosidase proteostasis. Nat Chem Biol, 6: 424\u2013432, 2010","journal-title":"Nat Chem Biol"},{"key":"864_CR42","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/auto.6.5.12047","volume":"6","author":"Y Sun","year":"2010","unstructured":"Sun Y, Grabowski GA. Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease. Autophagy, 6: 648\u2013649, 2010. (Epub ahead of print)","journal-title":"Autophagy"},{"key":"864_CR43","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4161\/auto.7.1.13884","volume":"7","author":"M Tatti","year":"2010","unstructured":"Tatti M, Motta M, Salvioli R. Autophagy in Gaucher disease due to saposin C deficiency. Autophagy, 7: 94\u201395, 2010","journal-title":"Autophagy"},{"issue":"Suppl 1","key":"864_CR44","first-page":"S34","volume":"47","author":"A Ballabio","year":"2009","unstructured":"Ballabio A. Disease pathogenesis explained by basic science: lysosomal storage diseases as autophagocytic disorders. Int J Clin Pharmacol Ther, 47(Suppl 1): S34\u2013S38, 2009","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-010-0864-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-010-0864-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-010-0864-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T10:23:18Z","timestamp":1592216598000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-010-0864-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":44,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1007\/s10354-010-0864-4","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}